131 related articles for article (PubMed ID: 24556596)
1. Bone marrow expression of CCL3 is not correlated with the extent of lytic bone lesions.
Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
Acta Haematol; 2014; 132(2):129-33. PubMed ID: 24556596
[No Abstract] [Full Text] [Related]
2. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
3. Insights from the gene expression profiling of multiple myeloma.
Claudio JO; Masih-Khan E; Stewart AK
Curr Hematol Rep; 2004 Jan; 3(1):67-73. PubMed ID: 14695854
[TBL] [Abstract][Full Text] [Related]
4. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
[TBL] [Abstract][Full Text] [Related]
5. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.
Bueno C; Lopes LF; Greaves M; Menendez P
Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665
[No Abstract] [Full Text] [Related]
6. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
Haaber J; Abildgaard N; Knudsen LM; Dahl IM; Lodahl M; Thomassen M; Kerndrup GB; Rasmussen T
Br J Haematol; 2008 Jan; 140(1):25-35. PubMed ID: 18005268
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.
Agnelli L; Storti P; Todoerti K; Sammarelli G; Dalla Palma B; Bolzoni M; Rocci A; Piazza F; Semenzato G; Palumbo A; Neri A; Giuliani N
Am J Hematol; 2011 Dec; 86(12):E64-6. PubMed ID: 21953534
[TBL] [Abstract][Full Text] [Related]
9. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
[TBL] [Abstract][Full Text] [Related]
10. c-Jun and GST-pi expression in human plasma cells.
Di Simone D; Galimberti S; Mattii L; Petrini M
Haematologica; 1997; 82(1):69-70. PubMed ID: 9107087
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma with Auer-rod-like inclusions.
Castoldi G; Piva N; Tomasi P
Haematologica; 1999 Sep; 84(9):859-60. PubMed ID: 10477463
[No Abstract] [Full Text] [Related]
12. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.
Hashimoto T; Abe M; Oshima T; Shibata H; Ozaki S; Inoue D; Matsumoto T
Br J Haematol; 2004 Apr; 125(1):38-41. PubMed ID: 15015966
[TBL] [Abstract][Full Text] [Related]
13. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
[No Abstract] [Full Text] [Related]
14. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.
Liu L; Yu Z; Cheng H; Mao X; Sui W; Deng S; Wei X; Lv J; Du C; Xu J; Huang W; Xia S; An G; Zhou W; Ma X; Cheng T; Qiu L; Hao M
Sci Rep; 2020 Nov; 10(1):20508. PubMed ID: 33239656
[TBL] [Abstract][Full Text] [Related]
15. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C; Zustin J; Jacobsen F; Luetkens T; Kröger N; Schilling G; Bokemeyer C; Sauter G; Atanackovic D; Marx A
Exp Mol Pathol; 2010 Oct; 89(2):175-81. PubMed ID: 20621094
[TBL] [Abstract][Full Text] [Related]
17. Biology and bioinformatics of myeloma cell.
Abroun S; Saki N; Fakher R; Asghari F
Lab Hematol; 2012 Dec; 18(4):30-41. PubMed ID: 23253865
[TBL] [Abstract][Full Text] [Related]
18. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
Pope B; Brown R; Luo XF; Gibson J; Joshua D
Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of HOXB7 gene in multiple myeloma and extramedullary multiple myeloma patients.
Novak EM; Linardi C; Metzger M; Maria DA; Giorgi RR; Moura F; Martinez GA; Bydlowski SP
Eur J Haematol; 2010 Feb; 84(2):185-6. PubMed ID: 19878270
[No Abstract] [Full Text] [Related]
20. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
